Association Between Immune-Related Adverse Events and Treatment Outcomes in Advanced Gastric Cancer Patients Receiving Nivolumab Plus Chemotherapy: A Retrospective Study.

ABSTRACT:

Background

Immune-related adverse events (irAEs) have been linked to improved outcomes in patients undergoing treatment with immune checkpoint inhibitors (ICIs) for various cancers. However, the relationship between irAEs and overall survival (OS) in patients with advanced gastric cancer (AGC) receiving chemoimmunotherapy remains unclear. This study aimed to explore the association between irAEs and treatment outcomes in patients with AGC receiving chemotherapy plus nivolumab.

Methods

This retrospective study analyzed clinical data from patients with HER2-negative AGC who received first-line chemotherapy (SOX, CapeOX, or FOLFOX) plus nivolumab at the National Cancer Center Hospital between November 2021 and February 2023. Patients were stratified into two groups based on the

SUBMITTER: Yamamoto K 

PROVIDER: S-EPMC12441737 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature